The therapeutic options for patients with advanced non–small-cell lung cancer (NSCLC) are
palliative. Therefore, the quality of life in oncology is considered as an endpoint in clinical …

Background Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients,
health care systems and society due to increasing incidence and poor survival rates. In …

Introduction Lung cancer, the most prevalent malignant cancer in the world, remains a
serious threat to public health. Recently, a large number of studies have shown that an …

Objectives: Pharmacogenomic applications in oncology offer significant promise, but the
clinical and economic implications remain unclear. The objective of this study was to …

Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …

Introduction Anaplastic lymphoma kinase (ALK) rearrangement gene testing is used
increasingly to identify patients with advanced non-small-cell lung cancer (NSCLC) who are …

Background Limited data exist regarding real-world treatment patterns, resource utilization,
and costs of extensive-stage small cell lung cancer (esSCLC) among elderly patients in the …

Background: There are few data on the cost-effectiveness of second-line chemotherapies for
non-small cell lung cancer (NSCLC). The objective of this phase III, randomized, multicenter …

Pemetrexed (Alimta®) is a multi-targeted antifolate cytotoxic agent available for use in the
treatment of adults with advanced non-squamous non-small cell lung cancer (NSCLC). It is …

In past decades, studies focusing on new chemotherapeutic agents for patients with
inoperable non-small-cell lung cancer have reported only modest gains in survival. These …